NRXP
NRX Pharmaceuticals IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$116.66M
P/E Ratio
—
EPS
$-1.04
Beta
2.02
52W High
$3.84
52W Low
$1.62
50-Day MA
$2.60
200-Day MA
$2.52
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
24.75
PEG Ratio
—
About NRX Pharmaceuticals Inc
NRx Pharmaceuticals, Inc., a clinical-stage small molecule pharmaceutical company, develops new treatments for the treatment of life-threatening central nervous system disorders and lung diseases. The company is headquartered in Wilmington, Delaware.
Fundamentals
| Revenue (TTM) | $2.29M |
| Gross Profit (TTM) | $1.16M |
| EBITDA | $-17.06M |
| Operating Margin | -444.60% |
| Return on Equity | -683.00% |
| Return on Assets | -110.20% |
| Revenue/Share (TTM) | $0.09 |
| Book Value | $-0.41 |
| Price-to-Book | 2.90 |
| Price-to-Sales (TTM) | 50.88 |
| EV/Revenue | 48.36 |
| EV/EBITDA | -0.15 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $36.23M |
| Float | $28.00M |
| % Insiders | 7.58% |
| % Institutions | 17.46% |
Historical Volatility
HV 10-Day
81.23%
HV 20-Day
61.10%
HV 30-Day
90.81%
HV 60-Day
89.78%
HV Rank
87.3%
Volatility is currently contracting
Analyst Ratings
Consensus ($40.40 target)
4
BuyMore HEALTHCARE Stocks
Data last updated: 5/25/2026